Second-Quarter 2012 Revenues of $15.1 Billion, excluding Discontinued Operations Revenues of $581 Million from the Nutrition(1) business
Second-Quarter 2012 Adjusted Diluted EPS(2) of $0.62; Second-Quarter 2012 Reported Diluted EPS(3) of $0.43
Reaffirms 2012 Financial Guidance
Repurchased $1.3 Billion of Common Stock in Second-Quarter 2012; Continue to Expect to Repurchase Approximately $5 Billion of Common Stock in 2012
Company Anticipates Filing a Registration Statement with the U.S. Securities and Exchange Commission by Mid-August for a Potential Initial Public Offering of up to a 20% Ownership Stake in the Animal Health Business, Zoetis

($ in millions, except per share amounts)
Second-Quarter 2012 2011(4) Change Year-to-Date 2012 2011(4) Change
Reported Revenues $ 15,057 $ 16,485 (9%) $ 29,942 $ 32,509 (8%)
Adjusted Income(2) 4,671 4,650 -- 9,015 9,359 (4%)
Adjusted Diluted EPS(2) 0.62 0.59 5% 1.19 1.17 2%
Reported Net Income(3) 3,253 2,610 25% 5,047 4,832 4%
Reported Diluted EPS(3) 0.43 0.33 30% 0.67 0.61 10%

See end of text prior to tables for notes.

NEW YORK, N.Y., Tuesday, July 31, 2012 – Pfizer Inc. (NYSE: PFE) today reported financial results for second-quarter 2012. Second-quarter 2012 revenues were $15.1 billion, a decrease of 9% compared with $16.5 billion in the year-ago quarter, which reflects an operational decline of $977 million, or 6%, and the unfavorable impact of foreign exchange of $451 million, or 3%.
For second-quarter 2012, U.S. revenues were $5.7 billion, a decrease of 15% compared with the year-ago quarter. This decrease was primarily the result of the U.S. loss of exclusivity of Lipitor on November 30, 2011. International revenues were $9.3 billion, a decrease of 5% compared -2- with the prior-year quarter, primarily due to the unfavorable impact of foreign exchange. U.S.
revenues represented 38% of total revenues in second-quarter 2012 compared with 41% in the year-ago quarter, while international revenues represented 62% of total revenues in secondquarter 2012 compared with 59% in the year-ago quarter.

zie meer op http://www.pfizer.com/files/investors/presentations/q2performance_073112.pdf